Select a Region North America

EVERSANA Recognized for Developing Multiple Top Innovations for 2023 by PM360 

CHICAGO – December 15, 2023 – EVERSANA®, a leading provider of commercialization services to the life sciences industry, today announced that two of its technology solutions have been named in the annual Top Innovations issue by PM360. 

ACTICS eAccess, EVERSANA’s new proprietary electronic benefits verification (eBV) and electronic prior authorization (ePA) platform, along with an Artificial Intelligence (AI) Interactive Assistant, developed to showcase the power of AI to transform patient interaction, were named to the 2023 PM360 Innovation Issue. PM360 has featured the top innovations across the pharmaceutical industry for 12 consecutive years.  

“Transforming an industry requires leveraging the power of technology to deliver new solutions to create better experiences,” said Jim Lang, CEO at EVERSANA. “To once again be recognized by PM360 for our next-generation offerings speaks to our team’s ability to rethink how services are delivered that ultimately deliver value to both our clients and patients. Congratulations to all those featured.” 

For more than a decade, the PM360 Innovation issue, published every December, has served as the industry’s guide to the latest and largest innovations across marketing, commercialization, R&D, and other categories. In 2023, a total of 56 innovations were selected by PM360’s editorial staff for inclusion from hundreds of nominations.

Submissions are evaluated by the editorial staff of PM360, and winners across sixteen categories are selected to be featured. This comprehensive overview of the year’s most innovative achievements helps companies in the industry find potential partners to help advance healthcare efforts around the globe. 

The full PM360 Innovation Issue can be found here. 



EVERSANA® is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit or connect through LinkedIn and X